JD.Com Inc vs Teladoc Health Inc — how do they compare? JD.Com Inc trades at $26.9 (market cap $36.62B), while Teladoc Health Inc trades at $5.54 (market cap $1.01B). The key difference: JD.Com Inc is far larger — about 36.3× Teladoc Health Inc's market cap, and JD.Com Inc pays a 3.72% dividend while Teladoc Health Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold JD.Com Inc for 85 Days and Teladoc Health Inc for 39 Days on average.
| JD | TDOC | |
|---|---|---|
Market Cap | $36.62B | $1.01B |
Volume | 6,571,477 | 4,668,477 |
Sector | Consumer Cyclical | Health |
52-Week High | $34.53 | $9.72 |
52-Week Low | $25.19 | $4.47 |
Typical Hold Time | 85 Days | 39 Days |
Enterprise Value | $19.26B | $1.27B |
Dividend Yield | 3.72% | — |
Signals from Pluang's Aura AI — not financial advice
JD.com is trading at $27.03, up 2.0% today, with strong analyst support showing 32 buy ratings versus just 1 sell. The stock demonstrates solid fundamentals with a low P/E of 17.98 and P/S of 0.2, trading below its $35.86 consensus price target. Recent earnings have consistently beaten expectations, though revenue growth has slowed in 2025 with net income margin declining to 1.13%. The company maintains a robust balance sheet with $234 billion in cash and is pursuing strategic acquisitions including the pending Ceconomy deal.
JD.com presents a compelling value opportunity with significant upside potential to analyst targets, supported by strong cash flow generation and consistent earnings beats. However, investors face risks from slowing revenue growth, regulatory scrutiny of international expansion, and competitive pressures in the Chinese e-commerce sector. The stock's current valuation appears attractive relative to peers, but requires monitoring of execution on strategic initiatives.
TDOC trades at $5.56, down 3.64% today, near multi-year lows with a bearish technical outlook. The stock shows mixed fundamentals with revenue stabilizing around $2.5B but persistent net losses, though improving from 2024's $1B loss to $200M in 2025. Valuation metrics appear attractive with P/S of 0.4 and EV/EBITDA of 5.9, while analyst consensus remains cautiously optimistic with a $8.83 price target.
The outlook remains challenged by ongoing losses and BetterHelp segment weakness, but potential exists if Integrated Care profitability improves and new CFO leadership executes effectively. Key risks include sustained negative cash flow, competitive pressures, and the ongoing SEC investigation highlighted in recent news.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
JD.com is China's second-largest e-commerce company after Alibaba in terms of gross merchandise volume, offering a wide selection of authentic products at competitive prices, with speedy and reliable delivery. The company has built its own nationwide fulfilment infrastructure and last-mile delivery network, staffed by its own employees, which supports both its online direct sales, its online marketplace and omnichannel businesses.
Read more on JD →Teladoc Health is a virtual health provider with a telehealth platform delivering 24-hour, on-demand healthcare via mobile devices, the internet, video, and phone. It also offers remote patient monitoring programs for chronic care management. Its platform connects members with a network of physicians and behavioral health professionals. Most of the company's revenue is generated from access fees on a subscription basis (per member, per month). The balance comes from visit fees and equipment rental and sales to hospital systems. Since inception, Teladoc has primarily partnered with employers, health plans, and health systems to offer network access to their members.
Read more on TDOC →